Undervalued Small-Cap Healthcare Stocks on NAS December 2024

December 09, 2024

Healthcare Sector

The healthcare sector includes companies in biotechnology, pharmaceuticals, hospitals, home and long-term care. It also includes related medical equipment manufacturers and suppliers.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Healthcare stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
AADI Aadi Bioscience - - 0.00 - 0 0.00 0.0
ABCL AbCellera Biologics - - 0.00 - 0 0.00 0.0
ABEO Abeona Therapeutics - - 0.00 - 0 0.00 0.0
ABOS Acumen Pharmaceuticals - - 0.00 - 0 0.00 0.0
ABP Abpro Hldgs - - 0.00 - 0 0.00 0.0
ABSI Absci - - 0.00 - 0 0.00 0.0
ABUS Arbutus Biopharma - - 0.00 - 0 0.00 0.0
ABVC ABVC BioPharma - - 0.00 - 0 0.00 0.0
ABVX Abivax - - 0.00 - 0 0.00 0.0
ACAD ACADIA Pharmaceuticals - - 0.00 - 0 0.00 24.1
All data provided as at market close December 08, 2024.

Company Details

Aadi Bioscience

AADI:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.

Access the stockcalc valuation


AbCellera Biologics

ABCL:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success.

Access the stockcalc valuation


Abeona Therapeutics

ABEO:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB).

Access the stockcalc valuation


Acumen Pharmaceuticals

ABOS:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Abpro Hldgs

ABP:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology.

Access the stockcalc valuation


Absci

ABSI:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Access the stockcalc valuation


Arbutus Biopharma

ABUS:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Access the stockcalc valuation


ABVC BioPharma

ABVC:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

Access the stockcalc valuation


Abivax

ABVX:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis.

Access the stockcalc valuation


ACADIA Pharmaceuticals

ACAD:NAS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

24.1

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Aadi Bioscience and AbCellera Biologics are the most undervalued Small-Cap Healthcare stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-small-cap-healthcare-stocks-nas-december-2024
Aadi Bioscience $AADI and AbCellera Biologics $ABCL are the most undervalued Healthcare stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-small-cap-healthcare-stocks-nas-december-2024
Aadi Bioscience and AbCellera Biologics are the most undervalued Small-Cap Healthcare stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-small-cap-healthcare-stocks-nas-december-2024

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.